#Innovent Biologics

Innovent Biologics Subsidiary Altruist Gains NMPA Approval for NDA Filing

Innovent Biologics subsidiary Altruist Biologics receives NMPA acceptance for a new drug application, validating its localized manufacturing platform and CDMO operational strategy.

Innovent Biologics Gains NMPA Nod for Sintilimab in Advanced Melanoma

Innovent Biologics advances its oncology pipeline as the NMPA accepts a new indication application for sintilimab to treat advanced melanoma, signaling potential…

Innovent Biologics Presents Phase 1 Data for IBI3001 at ESMO Congress

Innovent Biologics shares Phase 1 clinical trial results for IBI3001 at the ESMO congress, marking a key milestone in the company's oncology…

Innovent Biologics Phase 3 Trial Hits Primary Endpoints for Gastric Cancer

Innovent Biologics' G-HOPE-001 trial confirms clinical efficacy for its ADC candidate, marking a major milestone for the company's oncology pipeline and potential…

Innovent Biologics Expands Phase 3 MarsLight-11 Study for NSCLC Treatment

Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to…